Bal Pharma Limited
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services
What Bal files
- Others47
- Updates9
- Important9
- Board Meeting8
- Dividend/Bonus4
- Results2
Bal Pharma Limited has clarified that it possesses no undisclosed price-sensitive information or material updates that could account for recent significant fluctuations in its share price. The company confirmed that all necessary disclosures have been made on time and maintained full compliance with mandatory requirements. Management stated that the observed...
Bal Pharma has allotted 1,000,000 convertible warrants at ₹84 each to promoter Shailesh Siroya, aggregating to ₹8.40 Cr, raising 25% upfront (₹2.10 Cr). Warrants are convertible into equity within 18 months, boosting his potential stake from 17.24% to 20.89%.
Bal Pharma announced its 39th Annual General Meeting. The company also fixed the record date for shareholder eligibility for the proposed final dividend for FY25-26 and the cut-off date for e-voting. Book closure details were specified.
Bal Pharma clarified the utilization timeline for preferential issue proceeds. Funds from Convertible Warrants are slated for deployment within 18 months. There are no changes to the issue's objectives or how the capital will be used, providing clarity on future growth initiatives.
Bal Pharma's board approved the financial results for the quarter. An Investor Education and Protection Fund (IEPF) notice was issued for transferring shares with seven years of unclaimed dividends. Shareholders are advised to claim eligible shares and dividends.